Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

Lancet Respiratory Medicine,The - Tập 9 Số 12 - Trang 1407-1418 - 2021
Vincent C. Marconi1,2, Athimalaipet V Ramanan3,4, Stephanie de Bono5, Cynthia E. Kartman5, Venkatesh Krishnan5, Ran Liao5, Maria Lucia Buziqui Piruzeli5, Jason D. Goldman6,7, Jorge Alatorre-Alexander8, Rita de Cassia Pellegrini9, Vicente Estrada10, Mousumi Som11, Anabela Cardoso5, Sujatro Chakladar5, Brenda Crowe5, Paulo Reis5, Xin Zhang5, David H. Adams5, E. Wesley Ely12,13, Mi‐Young Ahn, Miriam Akasbi, Javier D. Altclas, Federico Ariel, Horacio Ariza, Chandrasekhar Atkar, Anselmo Bertetti, Monika Bhattacharya, María Luisa Briones, Akshay Budhraja, Aaliya Burza, Adrián Camacho Ortiz, Roberto Caricchio, Marcelo Casas, Virginia Recio, Won Suk Choi, Emilia Cohen, Angel Comulada-Rivera, Paul Cook5, D. Juarez, Christelle Daniel, Luís Relvas, Guillermo Domínguez‐Cherit, Todd B. Ellerin, Dmitry Enikeev, Suzana Érico Tanni, Elie Fiss, Motohiko Furuichi, Kléber Giovanni Luz, Omar Gonzalez, И. Г. Гордеев, Thomas Grünewald, Victor Augusto Hamamoto Sato, Eun Young Heo, Jung Yeon Heo, María Julia Hermida5, Yuji Hirai, David Hutchinson5, Claudio Iastrebner, Octavian C. Ioachimescu, Manish Jain, Maria Patelli Juliani Souza Lima, Akram Khan, Andreas E. Kremer, Thomas Lawrie, Mark MacElwee, Farah Madhani-Lovely, Vinay Malhotra, Michel F. Martínez‐Reséndez, James A. McKinnell, Patrick W. McGonagill, César Minelli, M. Mar Rodríguez, Maria Leonor Parody, Patricia Paulin, Priscilla Pemu, Ana Carolina Procopio Carvalho, Massimo Puoti, Joshua Purow, Mayur Ramesh, Álvaro Réa-Neto, Philip Robinson, Cristhieni Rodrigues, Gustavo Rojas‐Velasco, José Francisco Kerr Saraiva, Morton Scheinberg, Stefan Schreiber, Darío Scublinsky, Anete Sevciovic Grumach, Imad Shawa, J. C. Simon, Nidhi Sofat, Christoph D. Spinner, Eduardo Sprinz, Roger Scott Stienecker, José Suárez, Natsuo Tachikawa, Hasan Tahir, Brian Tiffany, Alexander Vishnevsky8, Adilson Westheimer Cavalcante, Kapil Zirpe
1Atlanta Veterans Affairs Medical Center, Decatur, GA, USA
2Emory University School of Medicine, Rollins School of Public Health and the Emory Vaccine Center, Atlanta, GA, USA
3Department of Paediatric Rheumatology, Bristol Royal Hospital for Children, Bristol, UK
4Translational Health Sciences, University of Bristol, Bristol, UK
5Eli Lilly and Company, Indianapolis, IN, USA
6Division of Allergy and Infectious Disease, Department of Medicine, University of Washington, Seattle, WA, USA
7Swedish Center for Research and Innovation, Swedish Medical Center, Providence St Joseph Health, Seattle, WA, USA
8Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico
9Pesquisare/Santo André, Brazil and Hospital Beneficência Portuguesa de São Caetano do Sul / São Caetano do Sul, Brazil
10Hospital Clinico San Carlos-IdiSSC, Universidad Complutense, Madrid, Spain
11Oklahoma State University Medicine, Internal Medicine—Houston Center, Tulsa, OK, USA
12Critical Illness, Brain Dysfunction, and Survivorship Center (CIBS), Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine at Vanderbilt University Medical Center, Nashville, TN, USA
13Tennessee Valley Veteran's Affairs Geriatric Research Education Clinical Center (GRECC), Nashville, TN, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 395, 497, 10.1016/S0140-6736(20)30183-5

Ruan, 2020, Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China, Intensive Care Med, 46, 846, 10.1007/s00134-020-05991-x

Siddiqi, 2020, COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal, J Heart Lung Transplant, 39, 405, 10.1016/j.healun.2020.03.012

Zhou, 2020, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, 395, 1054, 10.1016/S0140-6736(20)30566-3

Beigel, 2020, Remdesivir for the treatment of COVID-19—final report, N Engl J Med, 383, 1813, 10.1056/NEJMoa2007764

Kalil, 2021, Baricitinib plus remdesivir for hospitalized adults with Covid-19, N Engl J Med, 384, 795, 10.1056/NEJMoa2031994

Horby, 2021, Dexamethasone in hospitalized patients with COVID-19, N Engl J Med, 384, 693, 10.1056/NEJMoa2021436

2021, Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet, 397, 1637, 10.1016/S0140-6736(21)00676-0

Fridman, 2010, Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050, J Immunol, 184, 5298, 10.4049/jimmunol.0902819

Shi, 2014, The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers, J Clin Pharmacol, 54, 1354, 10.1002/jcph.354

McInnes, 2019, Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations, Arthritis Res Ther, 21, 183, 10.1186/s13075-019-1964-1

Sanchez, 2018, JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies, J Clin Invest, 128, 3041, 10.1172/JCI98814

Tanaka, 2016, Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomized placebo-controlled study, J Rheumatol, 43, 504, 10.3899/jrheum.150613

Dörner, 2020, Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways, Lupus Sci Med, 7, 10.1136/lupus-2020-000424

Richardson, 2020, Baricitinib as potential treatment for 2019-nCoV acute respiratory disease, Lancet, 395, e30, 10.1016/S0140-6736(20)30304-4

Stebbing, 2020, COVID-19: combining antiviral and anti-inflammatory treatments, Lancet Infect Dis, 20, 400, 10.1016/S1473-3099(20)30132-8

Stebbing, 2020, Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients, EMBO Mol Med, 12, 10.15252/emmm.202012697

Bronte, 2020, Baricitinib restrains the immune dysregulation in patients with severe COVID-19, J Clin Invest, 130, 6409, 10.1172/JCI141772

Petrone, 2021, In-vitro evaluation of the immunomodulatory effects of Baricitinib: implication for COVID-19 therapy, J Infect, 82, 58, 10.1016/j.jinf.2021.02.023

Sims, 2021, Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19, J Allergy Clin Immunol, 147, 107, 10.1016/j.jaci.2020.08.031

Titanji, 2021, Use of baricitinib in patients with moderate to severe coronavirus disease 2019, Clin Infect Dis, 72, 1247, 10.1093/cid/ciaa879

Cantini, 2020, Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact, J Infect, 81, 318, 10.1016/j.jinf.2020.04.017

Cantini, 2020, Beneficial impact of baricitinib in COVID-19 moderate pneumonia; multicentre study, J Infect, 81, 647, 10.1016/j.jinf.2020.06.052

Stebbing, 2021, JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality, Sci Adv, 7, 10.1126/sciadv.abe4724

Goletti, 2021, Baricitinib therapy in COVID-19 pneumonia—an unmet need fulfilled, N Engl J Med, 384, 867, 10.1056/NEJMe2034982

Gao, 2008, Sample size re-estimation for adaptive sequential design in clinical trials, J Biopharm Stat, 18, 1184, 10.1080/10543400802369053

Horby, 2020, Effect of dexamethasone in hospitalized patients with COVID-19—preliminary report, medRxiv

Cao, 2020, Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial, J Allergy Clin Immunol, 146, 137, 10.1016/j.jaci.2020.05.019

Guimarães, 2021, Tofacitinib in patients hospitalized with COVID-19 pneumonia, N Engl J Med, 385, 406, 10.1056/NEJMoa2101643

Hasan, 2021, Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh, BMC Infect Dis, 21, 427, 10.1186/s12879-021-06119-2

Thông tin
Thông tin xuất bản

Lancet Respiratory Medicine,The

Tập 9 Số 12

1407-1418

Thông tin tác giả